Posted on by ScienceFather
59 / 100
Powered by Rank Math SEO

Prof Dr. Dimos-Dimitrios Mitsikostas | Headache | Best Researcher Award

Prof Dr. Dimos-Dimitrios Mitsikostas, National & Kapodistrian University of Athens, Greece

🧠 Dimos D. Mitsikostas, MD, PhD, FEAN, is a prominent figure in neurology, specializing in headaches and multiple sclerosis (MS). As Professor of Neurology at NKUA, Greece, he leads the Headache Outpatient Clinic and Emergency Neurology. With over 200 peer-reviewed papers and an h-index of 52, his expertise spans headaches, placebo/nocebo effects, and MS. He co-chairs the Headache Scientific Panel at the European Academy of Neurology and presides over the Hellenic Headache Society. Prof. Mitsikostas completed his education at Aristotle’s University and pursued post-doc studies at Harvard Medical School and University College London. 🎓

Publication profile:

Scopus

Orcid

 

Employment:

🏥 Dimos Mitsikostas has been a steadfast presence at the National and Kapodistrian University of Athens since 2016, where he serves as Professor of Neurology in the esteemed 1st Neurology Department at Aeginition Hospital. As a dedicated educator and practitioner, he brings his expertise to the forefront, shaping the future of neurology in Athens and beyond. With a focus on advancing knowledge and treatment in his field, Prof. Mitsikostas contributes significantly to the academic and clinical landscape, ensuring patients receive top-tier care while inspiring the next generation of neurologists. 🧠

 

Education and qualifications:

📚 Dimos Mitsikostas began his journey in medicine at the prestigious Aristotle University of Thessaloniki, Greece, where he earned his MD from the School of Medicine. From 1979 to 1985, he immersed himself in the rigorous curriculum, laying the foundation for his illustrious career in neurology. This period of academic growth not only equipped him with medical expertise but also instilled in him a passion for advancing healthcare. Prof. Mitsikostas’s alma mater stands as a beacon of excellence, nurturing his intellect and shaping his dedication to improving neurological care worldwide. 🎓

 

Research Focus:

🔍 Dimos Mitsikostas’s research focus spans various aspects of neurology, with a particular emphasis on headaches and their management. As evidenced by his contributions to numerous peer-reviewed publications and clinical trials, he delves into understanding the mechanisms underlying headaches, exploring novel treatments, and addressing challenges such as placebo and nocebo effects. His work not only sheds light on the complexities of headache disorders but also aims to improve real-world effectiveness in their management. Through his dedication to advancing knowledge and treatment options, Prof. Mitsikostas plays a pivotal role in alleviating the burden of headaches for patients worldwide. 🧠

 

Publication Top Notes:

The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders

Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

Evidence-based symptomatic treatment of migraine

Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials

Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?

Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030

COVID-19 vaccination-related headache showed two different clusters in the long-term course: a prospective multicenter follow-up study (COVA-Head Study)

Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis

Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (RCVS)

Dimos-Dimitrios Mitsikostas | Headache | Best Researcher Award

You May Also Like